SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
MabCure, Inc. Receives U$500,000.00 Licensing Fee as Well as 12.5% Ongoing Royalty for Its Prostate Cancer Diagnostic Technology